Preview

Пульмонология

Расширенный поиск

Ингаляционные глюкокортикостероиды при хронической обструктивной болезни легких

https://doi.org/10.18093/0869-0189-2010-6-109-119

Полный текст:

Об авторе

С. Н. Авдеев
ФГУ "НИИ пульмонологии" ФМБА России
Россия


Список литературы

1. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2009

2. www.goldcopd.org

3. Celli B.R., MacNee W. ATS / ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946

4. Buist A.S., McBurnie M.A., Vollmer W.M. et al. Inter� national variation in the prevalence of COPD (the BOLD Study): a population�based prevalence study. Lancet 2007; 370: 741-750

5. Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morbid. Mortal. Wkly Rep. Surveill Summ. 2002; 51: 1-16

6. Murray C.J., Lopez A.D. Alternative projections of mortal� ity and disability by cause 1990-2020: Global burden of disease study. Lancet 1997; 349: 1498-1504

7. Wise R.A., Tashkin D.P. Optimizing treatment of chronic obstructive pulmonary disease: An assessment of current therapies. Am. J. Med. 2007; 120: 4-13

8. Celli B.R. Update on the management of COPD. Chest 2008; 133: 1451-1462

9. Tashkin D.P., Celli B., Senn S. et al. for the UPLIFT Study Investigators. A 4�year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554

10. Decramer M., Celli B., Kesten S. et al. for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a ran� domised controlled trial. Lancet 2009; 374: 1171-1178

11. Rennard S.I., Anderson W., ZuWallack R. et al. Use of a long�acting inhaled β2�adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092

12. Dahl R., Greefhorst L.A., Nowak D. et al. Inhaled for� moterol dry powder versus ipratropium bromide in chron� ic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 778-784

13. Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow�release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069

14. Hogg J.C. Pathophysiology of airflow limitation in chron� ic obstructive pulmonary disease. Lancet 2004; 364: 709-721

15. Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long�term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340: 1948-1953

16. Burge P.S., Calverley P.M., Jones P.W. et al. on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary dis� ease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303

17. Lung Health Study Research Group. Effect of inhaled tri� amcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909

18. Cazzola M., Dahl R. Inhaled combination therapy with long�acting β2�agonists and corticosteroids in stable COPD. Chest 2004; 126: 220-237

19. Hanania N.A. The impact of inhaled corticosteroid and long�acting β�agonist combination therapy on outcomes in COPD. Pulmon. Pharmacol. Ther. 2008; 21: 540-550

20. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int. J. Clin. Pract. 2009; 63: 1136-1149

21. Barnes P.J. Scientific rationale for inhaled combination therapy with long�acting beta2�agonists and corticos� teroids. Eur. Respir. J. 2002; 19: 182-191

22. Finney P.A., Donnelly L.E., Belvisi M.G. et al. Chronic sys� temic administration of salmeterol to rats promotes pul� monary beta(2)�adrenoceptor desensitization and down� regulation of G(s alpha). Br. J. Pharmacol. 2001; 132: 1261-1270

23. Giembycz M.A., Kaur M., Leigh R., Newton R. A Holy Grail of asthma management: toward understanding how long�acting β2�adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br. J. Pharmacol. 2008; 153: 1090-1104

24. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstruc� tive pulmonary disease: molecular and cellular mecha� nisms. Eur. Respir. J. 2003; 22: 672-688

25. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 2004; 56: 515-548

26. Barnes P.J. Macrophages as orchestrators of COPD. J. COPD 2004; 1: 59-70

27. Burgel P.R., Nadel J.A. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin pro� duction in airway epithelium. Thorax 2004; 59: 992-996

28. Saetta M., Turato G., Maestrelli P. et al. Cellular and struc� tural bases of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1304-1309

29. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Associa� tion between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta� analysis. Thorax 2004; 59: 574-580

30. Agusti A.G., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 347-360

31. Wouters E.F., Creutzberg E.C., Schols A.M. Systemic effects in COPD. Chest 2002; 121 (Suppl. 5): 127S-130S

32. Keatings V.M., Jatakanon A., Worsdell Y.M. et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 1997; 155: 542-548

33. Culpitt S.V., Maziak W., Loukidis S. et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1635-1639

34. Gan W.Q., Man S.F., Sin D.D. Effects of inhaled corticos� teroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta�analy� sis. BMC Pulm. Med. 2005; 5: 3

35. Hattotuwa K.L., Gizycki M.J., Ansari T.W. et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double�blind, placebo� controlled biopsy study. Am. J. Respir. Crit. Care Med. 2002; 165: 1592-1596

36. Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol / fluticasone propionate on airway inflam� mation in COPD: a randomised controlled trial. Thorax 2007; 62: 938-943

37. Lapperre T.S., SnoeckStroband J.B., Gosman M.M. et al. Effect of fluticasone with and without salmeterol on pul� monary outcomes in chronic obstructive pulmonary dis� ease: a randomized trial. Ann. Intern. Med. 2009; 151: 517-527

38. Barnes N.C., Qiu Y.S., Pavord I.D. et al. Antiinflamma� tory effects of salmeterol / fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736-743

39. Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25: 552-563

40. Ito K., Ito M., Elliott W.M. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary dis� ease. N. Engl. J. Med. 2005; 352: 1967-1976

41. Sin D.D., Lacy P., York E., Man S.F. Effects of fluticasone on systemic markers of inflammation in chronic obstruc� tive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 760-765

42. Sin D.D., Man S.F., Marciniuk D.D. et al. The effects of fluticasone with or without salmeterol on systemic bio� markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 1207-1214

43. Man P.S.F., Zhang X., Vessey R. et al. The effects of inhaled and oral corticosteroids on serum inflammatory biomark� ers in COPD: an exploratory study. Ther. Adv. Respir. Dis. 2009; 3: 73-80

44. Huiart L., Ernst P., Ranouil X., Suissa S. Low�dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur. Respir. J. 2005; 25: 634-639

45. Macie C., Wooldrage K., Manfred J. et al. Inhaled corticos� teroids and mortality in COPD. Proc. Am. Thorac. Soc. 2005; 2: A91

46. Sin D.D., Wu L., Anderson J.A. et al. Inhaled corticos� teroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997

47. Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible pro� tection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115-1159

48. Loke Y.K., Kwok C.S., Singh S. Risk of myocardial infarc� tion and cardiovascular death associated with inhaled cor� ticosteroids in COPD: a systematic review and meta� analysis. Eur. Respir. J. 2010; 35: 1003-1021

49. Kiri V.A., Fabbri L.M., Davis K.J., Soriano J.B. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir. Med. 2009; 103: 85-90

50. Vestbo J., Sorensen T., Lange P. et al. Long�term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823

51. van der Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358-1363

52. Wouters E.F., Postma D.S., Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol / fluti� casone treatment in patients with COPD causes immedi� ate and sustained disease deterioration: a randomised con� trolled trial. Thorax 2005; 60: 480-487

53. Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789

54. Calverley P., Pauwels R., Vestbo J. et al. Combined salme� terol and fluticasone in the treatment of COPD: a ran� domised controlled trial. Lancet 2003; 361 (9356): 449-456

55. Suissa S., Barnes P.J. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 2009; 34: 13-16

56. Postma D.S., Calverley P. Inhaled corticosteroids in COPD - a case in favour. Eur. Respir. J. 2009; 34: 10-12

57. Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332-338

58. Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive disease. Eur. Respir. J. 2003; 21: 74-81

59. Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919

60. Halpin D.M.G. Evaluating the effectiveness of combina� tion therapy to prevent COPD exacerbations: the value of NNT analysis. Int. J. Clin. Pract. 2005; 59: 1187-1194

61. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tio� tropium in combination with placebo, salmeterol, or fluti� casone�salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555

62. Schermer T., Chavannes N., Dekhuijzen R. et al. Fluti� casone and N�acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103: 542-551

63. de Melo M.N., Ernst P., Suissa S. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients. Eur. Respir. J. 2004; 23: 692-697

64. Agarwal R., Aggarwal A.N., Gupta D, Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerba� tions. A systematic review and metaregression of random� ized controlled trials. Chest 2010; 137; 318-325

65. Cyr M.C., Beauchesne M.F., Lemière C. et al. Effects of inhaled corticosteroids in monotherapy or combined with long�acting β2�agonists on mortality among patients with chronic obstructive pulmonary disease. Ann. Pharmaco� therapy 2010; 44: 613-622

66. Kliber A., Lynd L.D., Sin D.D. The effects of long�acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease. Respir. Res. 2010; 11: 56

67. Sin D.D., McAlister F.A., Man S.F., Anthonisen N.R. Con� temporary management of chronic obstructive pulmonary disease: scientific review. J.A.M.A. 2003; 290: 2301-2312

68. Suissa S., Ernst P., Vandemheen K.L. et al. Methodological issues in therapeutic trials of COPD. Eur. Respir. J. 2008; 31: 927-933

69. Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur. Respir. J. 2008; 32: 829-831

70. La Vecchia C., Fabbri L.M. Prevention of death in COPD. N. Engl. J. Med. 2007; 356: 2211-2212

71. Brightling C.E., Monteiro W., Ward R. et al. Sputum eosinophilia and short�term response to prednisolone in chronic obstructive pulmonary disease: a randomised con� trolled trial. Lancet 2000; 356: 1480-1485

72. Kerstjens H.A.M., Brand P.L.P., Hughes M.D. et al. A com� parison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N. Engl. J. Med. 1992; 327: 1413-1419

73. Kerstjens H.A.M., Overbeek S.E., Schouten J.P. et al. Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long�term inhaled corticosteroid treatment. Eur. Respir. J. 1993; 6: 868-876

74. Verhoeven G.T., Hegmans J.P., Mulder P.G. et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002; 57: 694-700

75. Leuppi J.D., Tandjung R., Anderson S.D. et al. Prediction of treatment�response to inhaled corticosteroids by manni� tol�challenge test in COPD. A proof of concept. Pulm. Pharmacol. Ther. 2005; 18: 83-88

76. Leigh R., Pizzichini M.M.M., Morris M.M. et al. Stable COPD: predicting benefit from high�dose inhaled corti� costeroid treatment. Eur. Respir. J. 2006; 27: 964-971

77. Brightling C.E., McKenna S., Hargadon B. et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60: 193-198

78. Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur. Respir. J. 2010; 35: 72-78

79. Tashkin D.P., Murray H.E., Skeans M. et al. Skin manifes� tations of inhaled corticosteroids in COPD patients. Results from Lung Health Study II. Chest 2004; 126: 1123-1133

80. Etminan M., Sadatsafavi M., Ganjizade Zavareh S. et al. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta�analysis. Drug. Saf. 2008; 31: 409-414

81. Hubbard R.F., Tattersfield A.F., Smith C.F. et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130: 1687-1688

82. Hubbard R.B., Smith C.J., Smeeth L. et al. Inhaled corti� costeroids and hip fracture: a population�based case�con� trol study. Am. J. Respir. Crit. Care Med. 2002; 166: 1563-1566

83. Lee T.A., Weiss K.B. Fracture risk associated with inhaled corticosteroid use in COPD. Am. J. Respir. Crit. Care Med. 2004; 169: 855-859

84. Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bron� chodilator drugs and inhaled and oral corticosteroids. Chest 2007; 13: 1599-1560

85. Israel E., Banerjee T.R., Fitzmaurice G.M. et al. Effects of inhaled glucocorticoids on bone density in premenopausal women. N. Engl. J. Med. 2001; 345: 941-947

86. Ferguson G.T., Calverley P.M., Anderson J.A. et al. Prevalence and progression of osteoporosis in patients with COPD: results from the towards a revolution in COPD health study. Chest 2009; 136: 1456-1465

87. Weatherall M., Clay J., James K. et al. Dose�response rela� tionship of inhaled corticosteroids and cataracts: a systemat� ic review and meta�analysis. Respirology 2009; 14: 983-990

88. Uboweja A., Malhotra S., Pandhi P. Effect of inhaled corti� costeroids on risk of development of cataract: a meta� analysis development of cataract: a meta�analysis. Fundam. Clin. Pharmacol. 2006; 20: 305-309

89. Gonzalez A.V., Li G., Suissa S., Ernst P. Risk of glaucoma in elderly patients treated with inhaled corticosteroids for chronic airflow obstruction. Pulm. Pharmacol. Ther. 2010; 23: 65-70

90. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123: 1001-1006

91. Kardos P., Wencker M., Glaab T., Vogelmeier C. Impact of salmeterol / fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary dis� ease. Am. J. Respir. Crit. Care Med. 2007; 175: 144-149

92. Wedzicha J.A., Calverley P.M.A., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacer� bations by salmeterol / fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26

93. Anzueto A., Ferguson G.T., Feldman G. et al. Effect of fluti� casone propionate / salmeterol (250 / 50) on COPD exac� erbations and impact on patient outcomes. COPD 2009; 6: 320-329

94. Ernst P., Gonzalez A.V., Brassard P. et al. Inhaled corticos� teroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am. J. Respir. Crit. Care Med. 2007; 176: 162-166

95. Авдеев С.Н., Баймаканова Г.Е. Ингаляционные глюко� кортикостероиды и риск развития пневмонии у боль� ных хронической обструктивной болезнью легких. Пульмонология 2010; 5: 101-109

96. Lapperre T.S. Airway pathology in COPD: smoking cessa� tion and pharmacological treatment intervention. Results from the GLUCOLD study. D.Sc. Thesis. Printed by: Pasmans Offsetdrukkerij B.V., Den Haag. 2009: 1-167

97. Grashoff W.F., Sont J.K., Sterk P.J. et al. Chronic obstruc� tive pulmonary disease: role of bronchiolar mast cells and macrophages. Am. J. Pathol. 1997; 151: 1785-1790

98. John M., Bosse S., Oltmanns U. et al. Effects of inhaled HFA beclomethasone on pulmonary function and symp� toms in patients with chronic obstructive pulmonary dis� ease. Respir. Med. 2005; 99: 1418-1424

99. Calverley P.M., Kuna P., Monsó E. et al. Beclomethasone / formoterol in the management of COPD: A randomised controlled trial. Respir. Med. 2010; 104: 1858-1868

100. Drummond M.B., Dasenbrook E.C., Pitz M.W. et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta�analysis. J.A.M.A. 2008; 300: 2407-2416


Для цитирования:


Авдеев С.Н. Ингаляционные глюкокортикостероиды при хронической обструктивной болезни легких. Пульмонология. 2010;(6):109-119. https://doi.org/10.18093/0869-0189-2010-6-109-119

Просмотров: 7


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)